Dose-Escalated Stereotactic Versus Conventional Radiotherapy for Painful Bone Metastases (ROBOMET): A Multicenter, Patient-Blinded Randomized Clinical Trial
Journal of Clinical Oncology · 2025-07 · 43 (19) · 2164-2172
DOI: 10.1200/jco-24-01447 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, 2025-07. Verfasst von Carole Mercier und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Iridium Network, Wilrijk (Antwerp), Belgium. Hauptthemen laut MEDLINE: Radiosurgery, Bone Neoplasms, Cancer Pain, Radiotherapy, Conformal. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 28 Literaturangaben.
Abstract (Originalsprache)
PURPOSE To test whether dose-escalated single fraction (SF) stereotactic body radiotherapy (SBRT) of 20 Gy to painful bone metastases is superior to conventional SF three-dimensional (3D) conformal radiotherapy (RT) to a standard dose of 8 Gy in achieving complete pain response (CR). METHODS A single-blind, randomized, controlled, phase III trial (ROBOMET) included 126 patients with up to three painful bone metastases, randomly assigned between April 2019 and October 2022 at multiple centers in Belgium. Inclusion criteria were uncomplicated painful bone metastases (worst pain score ≥2 on a 0-10 pain scale) arising from a solid tumor. Treatment consisted of either a single SBRT fraction of 20 Gy or a single conventional RT fraction of 8 Gy. The primary end point was the proportion of patients with a CR 1 month after RT scored according to the International Consensus on Palliative Radiotherapy Endpoints analyzed as per an intention-to-treat principle. RESULTS After 1 month, 16 of 63 (25% [95% CI, 15 to 38]) patients treated with conventional RT achieved CR versus 23 of 63 (37% [95% CI, 25 to 50]) treated with SBRT ( P = .25). After 3 months, 15 of 63 (24% [95% CI, 14 to 36]) patients achieved CR after conventional RT versus 21 of 63 (33% [95% CI, 22 to 46]) after SBRT ( P = .32). Among patients evaluable after 3 months and treated per protocol, the SBRT group had more complete responders (21/39, 54% [95% CI, 37 to 70]) than the conventional RT group (15/48, 31% [95% CI, 19 to 46]; P = .048). CONCLUSION SBRT failed to demonstrate improved CR rates after 1 month.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Radiation Oncology, Iridium Network, Wilrijk (Antwerp), Belgium.
- Integrated Personalised and Precision Oncology Network, University Antwerp, Antwerp, Belgium.
- Department of Human Structure and Repair, Ghent University, Ghent, Belgium.
- Department of Radiation Oncology, University Hospital Ghent, Gent, Belgium.
- Translational Cancer Research Unit (TCRU)-GZA Ziekenhuizen, Wilrijk (Antwerp), Belgium.
- Department of Medical Oncology, GZA Ziekenhuizen Sint-Augustinus, Wilrijk-Antwerp, Belgium.
ORCID-Profile: Carole Mercier, Piet Ost, Katrien Vandecasteele, Yolande Lievens, Dirk Verellen, Piet Dirix
Zitieren
APA
Mercier, C., Billiet, C., Ost, P., Vandecasteele, K., De Kerf, G., Claessens, M., Van Laere, S., Vermeulen, P., Dirix, L., Lievens, Y., Verellen, D., & Dirix, P. (2025). Dose-Escalated Stereotactic Versus Conventional Radiotherapy for Painful Bone Metastases (ROBOMET): A Multicenter, Patient-Blinded Randomized Clinical Trial. Journal of Clinical Oncology, 43(19), 2164-2172. https://doi.org/10.1200/jco-24-01447
Vancouver
Mercier C, Billiet C, Ost P, Vandecasteele K, De Kerf G, Claessens M, et al. Dose-Escalated Stereotactic Versus Conventional Radiotherapy for Painful Bone Metastases (ROBOMET): A Multicenter, Patient-Blinded Randomized Clinical Trial. Journal of Clinical Oncology. 2025;43(19):2164-2172. doi:10.1200/jco-24-01447
BibTeX
@article{Mercier2025,
author = {Mercier, Carole and Billiet, Charlotte and Ost, Piet and Vandecasteele, Katrien and De Kerf, Geert and Claessens, Michaël and Van Laere, Steven and Vermeulen, Peter and Dirix, Luc and Lievens, Yolande and Verellen, Dirk and Dirix, Piet},
title = {Dose-Escalated Stereotactic Versus Conventional Radiotherapy for Painful Bone Metastases (ROBOMET): A Multicenter, Patient-Blinded Randomized Clinical Trial},
journal = {Journal of Clinical Oncology},
year = {2025},
volume = {43},
number = {19},
pages = {2164--2172},
doi = {10.1200/jco-24-01447}
}
EUVIMED